FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3156822015> ?p ?o ?g. }

• W3156822015 endingPage "1845" @default.
• W3156822015 startingPage "1845" @default.
• W3156822015 abstract "AMHRII, the anti-Müllerian hormone receptor, is selectively expressed in normal sexual organs but is also re-expressed in gynecologic cancers. Hence, we developed murlentamab, a humanized glyco-engineered anti-AMHRII monoclonal antibody currently in clinical trial. Low-fucosylated antibodies are known to increase the antibody-dependent cell-mediated cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP) potency of effector cells, but some preliminary results suggest a more global murlentamab-dependent activation of the immune system. In this context, we demonstrate here that the murlentamab opsonization of AMHRII-expressing ovarian tumor cells, in the presence of unstimulated- or tumor-associated macrophage (TAM)-like macrophages, significantly promotes macrophage-mediated ADCC and shifts the whole microenvironment towards a pro-inflammatory and anti-tumoral status, thus triggering anti-tumor activity. We also report that murlentamab orients both unstimulated- and TAM-like macrophages to an M1-like phenotype characterized by a strong expression of co-stimulation markers, pro-inflammatory cytokines and chemokines, favoring T cell recruitment and activation. Moreover, we show that murlentamab treatment shifts CD4+ Th1/Th2 balance towards a Th1 response and activates CD8+ T cells. Altogether, these results suggest that murlentamab, through naïve macrophage orientation and TAM reprogrammation, stimulates the anti-tumor adaptive immune response. Those mechanisms might contribute to the sustained clinical benefit observed in advanced cancer patients treated with murlentamab. Finally, the enhanced murlentamab activity in combination with pembrolizumab opens new therapeutic perspectives." @default.
• W3156822015 created "2021-04-26" @default.
• W3156822015 creator A5009811771 @default.
• W3156822015 creator A5016310131 @default.
• W3156822015 creator A5020914724 @default.
• W3156822015 creator A5031285755 @default.
• W3156822015 creator A5037111341 @default.
• W3156822015 creator A5058846502 @default.
• W3156822015 creator A5062766256 @default.
• W3156822015 creator A5063736712 @default.
• W3156822015 creator A5067527341 @default.
• W3156822015 creator A5068459453 @default.
• W3156822015 creator A5069319423 @default.
• W3156822015 creator A5082116418 @default.
• W3156822015 creator A5083396561 @default.
• W3156822015 creator A5083741321 @default.
• W3156822015 creator A5084741022 @default.
• W3156822015 date "2021-04-13" @default.
• W3156822015 modified "2023-10-13" @default.
• W3156822015 title "Murlentamab, a Low Fucosylated Anti-Müllerian Hormone Type II Receptor (AMHRII) Antibody, Exhibits Anti-Tumor Activity through Tumor-Associated Macrophage Reprogrammation and T Cell Activation" @default.
• W3156822015 cites W1559033760 @default.
• W3156822015 cites W1639311959 @default.
• W3156822015 cites W1985572296 @default.
• W3156822015 cites W1990440494 @default.
• W3156822015 cites W2011440748 @default.
• W3156822015 cites W2012416768 @default.
• W3156822015 cites W2038955710 @default.
• W3156822015 cites W2062368870 @default.
• W3156822015 cites W2075901113 @default.
• W3156822015 cites W2081867678 @default.
• W3156822015 cites W2082554712 @default.
• W3156822015 cites W2084136419 @default.
• W3156822015 cites W2092741156 @default.
• W3156822015 cites W2093705034 @default.
• W3156822015 cites W2096617104 @default.
• W3156822015 cites W2101195992 @default.
• W3156822015 cites W2108556253 @default.
• W3156822015 cites W2109440389 @default.
• W3156822015 cites W2112390984 @default.
• W3156822015 cites W2128933541 @default.
• W3156822015 cites W2132094713 @default.
• W3156822015 cites W2133626640 @default.
• W3156822015 cites W2137354517 @default.
• W3156822015 cites W2137695731 @default.
• W3156822015 cites W2138165502 @default.
• W3156822015 cites W2157544609 @default.
• W3156822015 cites W2162166699 @default.
• W3156822015 cites W2163196794 @default.
• W3156822015 cites W2466883271 @default.
• W3156822015 cites W2526413860 @default.
• W3156822015 cites W2552470435 @default.
• W3156822015 cites W2582686270 @default.
• W3156822015 cites W2589146359 @default.
• W3156822015 cites W2726149797 @default.
• W3156822015 cites W2751197444 @default.
• W3156822015 cites W2756896022 @default.
• W3156822015 cites W2760914372 @default.
• W3156822015 cites W2769275108 @default.
• W3156822015 cites W2806738650 @default.
• W3156822015 cites W2810317548 @default.
• W3156822015 cites W2887941629 @default.
• W3156822015 cites W2891028652 @default.
• W3156822015 cites W2898415660 @default.
• W3156822015 cites W2954737082 @default.
• W3156822015 cites W2957498182 @default.
• W3156822015 cites W2972265332 @default.
• W3156822015 cites W2974291499 @default.
• W3156822015 cites W2974844477 @default.
• W3156822015 cites W2976946665 @default.
• W3156822015 cites W2982017357 @default.
• W3156822015 cites W2983051519 @default.
• W3156822015 cites W3033530735 @default.
• W3156822015 cites W3046770314 @default.
• W3156822015 cites W3048558989 @default.
• W3156822015 cites W4213245349 @default.
• W3156822015 doi "https://doi.org/10.3390/cancers13081845" @default.
• W3156822015 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8070390" @default.
• W3156822015 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33924378" @default.
• W3156822015 hasPublicationYear "2021" @default.
• W3156822015 type Work @default.
• W3156822015 sameAs 3156822015 @default.
• W3156822015 citedByCount "4" @default.
• W3156822015 countsByYear W31568220152021 @default.
• W3156822015 countsByYear W31568220152022 @default.
• W3156822015 countsByYear W31568220152023 @default.
• W3156822015 crossrefType "journal-article" @default.
• W3156822015 hasAuthorship W3156822015A5009811771 @default.
• W3156822015 hasAuthorship W3156822015A5016310131 @default.
• W3156822015 hasAuthorship W3156822015A5020914724 @default.
• W3156822015 hasAuthorship W3156822015A5031285755 @default.
• W3156822015 hasAuthorship W3156822015A5037111341 @default.
• W3156822015 hasAuthorship W3156822015A5058846502 @default.
• W3156822015 hasAuthorship W3156822015A5062766256 @default.
• W3156822015 hasAuthorship W3156822015A5063736712 @default.
• W3156822015 hasAuthorship W3156822015A5067527341 @default.
• W3156822015 hasAuthorship W3156822015A5068459453 @default.
• W3156822015 hasAuthorship W3156822015A5069319423 @default.
• W3156822015 hasAuthorship W3156822015A5082116418 @default.

• next